Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 6 | BMC Cancer

Fig. 6

From: Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms

Fig. 6

Co-treatment with HHT and bortezomib suppresses tumor growth in murine xenograft models and prolongs animal survival. NOD/SCID-γ mice were subcutaneously inoculated in the right rear flank with 10 × 106 SU-DHL-4/Luc (a) and U2932/Luc (b) cells which stably express luciferase. Treatment was initiated after the tumor were visualized, measured, and randomly grouped 10 days after injection of tumor cells. HHT was administrated at a dose of 1 mg/kg by i.p 5 days a week. Bortezomib was administered at a dose of 0.75 mg/kg i.p twice a week. Control animals were administered equal volumes of vehicle. a Tumor growth (SU-DH-L4) was monitored twice weekly by injection of luciferin and imaged by the IVIS 200 imaging system. d = day, empty boxes represent deceased mice. b Kaplan–Meier analysis was performed to analyze survival of animals. The survival of mice treated with the combination was significantly prolonged compared to mice treated with single agents (p < 0.05). c Tumor growth (U2932) was monitored twice weekly by injection of luciferin and imaged by the IVIS 200 imaging system. d = day, empty boxes represent deceased mice. b Kaplan–Meier analysis was performed to analyze survival of animals. The survival of mice treated with the combination was significantly prolonged compared to mice treated with single agents (p < 0.02)

Back to article page